Articles tagged with Antibodies
Researchers have developed a new diagnostic test called p-LFAs that can detect and quantify protein concentrations to identify bacterial and viral infections. The test is 1,000 times more sensitive than conventional tests, returning results in just 20 minutes.
Researchers develop eRapid sensor technology to detect SARS-CoV-2 antibodies, enabling fast and multiplexed testing at the point-of-care. The device distinguishes between antibody types targeting different viral proteins with high sensitivity and specificity.
Researchers from the University of Southampton have discovered that changing how tightly an antibody binds to a target can improve cancer treatments. By reducing affinity, immunomodulatory antibodies can effectively fine-tune the antibody to the desired level and activity.
Researchers developed a vaccine platform that uses nanoscopic particles to deliver antigens, which can stimulate immune responses. The platform showed promise in early trials with mice, with improved survival rates against influenza and HIV.
Researchers at La Jolla Institute for Immunology have discovered the detailed mechanism of action of Inmazeb, a three-antibody cocktail designed to combat Ebola virus infection. The study reveals new information about how the drug interacts with the virus and its potential effectiveness against additional species of Ebolavirus.
A study by OHSU researchers found that immunity from COVID-19 gathers strength over time, indicating that vaccination should not be delayed. The study suggests that vaccine boosters can be spaced no more frequently than a year apart among healthy individuals.
Researchers will investigate how ducks' immune systems act as a reservoir for the highly infectious H5N1 virus and engineer antibodies to prevent transmission to other animals and humans. They aim to develop ways to purify antibody-producing cells from ducks and assemble a pool of antibodies to understand their molecular features.
A new study provides evidence on when OAS occurs and how it impacts seasonal vaccines and booster shots. The findings suggest that boosting against a new strain can be effective if the new strain is sufficiently different from the previous one.
Researchers found women's immune responses to herpes simplex virus (HSV) vaccine are stronger, while those with prior exposure have different type I IFN signatures. This interaction may affect vaccine effectiveness.
Researchers found that high levels of mucosal IgA antibodies in the airways protect against SARS-CoV-2 infection for at least eight months, with a 90% lower risk of re-infection. Participants with prior infections generated stronger mucosal immune responses to Omicron breakthrough infections.
A new method for rapid and specific antibody detection has been introduced, using programmable gene circuits, cell-free transcription, and electrochemical detection. The system can detect antibodies in complex samples such as blood serum and is adaptable for a wide variety of other antibodies.
A new study published in the Journal of Perinatology found that breast milk from vaccinated parents contains antibodies that provide protection to infants. The study analyzed stool samples from 25 infants and found SARS-CoV-2 antibodies, which offer protection against the virus.
A team of researchers from Erlangen and Würzburg developed a method to bind specific molecules in samples and serums to iron oxide particles, allowing for their identification using an inexpensive and compact detector. This method enables highly sensitive measurements in a short time with little technical outlay.
A new analysis by Cedars-Sinai investigators shows that similar levels of COVID-19 antibodies are reached over an extended period of time in different population groups. Individuals with autoimmune diseases and solid organ transplant patients experience lower long-term antibody levels.
Researchers have made a breakthrough in precision oncology for patients with metastatic urothelial carcinoma, identifying that certain cell surface molecules decrease or are absent in these patients, making them resistant to the new drug enfortumab vedotin.
A new study reveals that long-lived germinal centers, which can last for six months, are maintained by a dynamic balance between founder B cells and newly introduced naive B cells. The research provides insights into the workings of these microscopic training grounds and could inform future vaccine design.
A new study from the University of Virginia Health System found that mRNA booster shots increase the durability of antibodies to COVID-19. The boosters led to longer-lasting antibodies, even in those who had previously recovered from a COVID-19 infection.
Researchers developed a method to estimate seroprevalence using blood donation samples, offering insights into the first year of the COVID-19 epidemic in Brazil. The study found significant differences among regions and subgroups, highlighting the need for real-time tracking and forecasting of future waves.
Research suggests individuals experiencing COVID-19-related chemosensory deficits are more likely to develop high antibody levels against SARS-CoV-2. This study's findings imply a link between impaired senses and robust immune response.
Researchers developed an accurate predictive model to distinguish between COVID-19 positive and negative test outcomes. The study found that symptom features, such as fever and difficulty breathing, play a significant role in predicting test results, with molecular tests yielding lower positive rates due to their dependence on viral load.
A large study found that most Canadian children and adults younger than 60 had been exposed to SARS-CoV-2 through a combination of vaccination and infection. The study, conducted in British Columbia, shows a dramatic change in the proportion of the population with antibodies over the first 2.5 years of the pandemic.
A study conducted in Brazil reveals that only 75.8% of under-fifteen children in São Paulo have antibodies against measles, falling short of the ideal 94% target to prevent outbreaks. The finding is a warning sign that Brazilian children are not achieving herd immunity, making them susceptible to infection.
A Brazilian team developed an electrochemical immunosensor to detect SARS-CoV-2 antibodies, achieving 88.7% sensitivity and 100% specificity in just five minutes. The device can be adapted for other diseases and has potential for monitoring seroconversion and seroprevalence.
A systematic review and meta-analysis of ADC clinical trials found that 91.2% of patients experienced treatment-related adverse events, with serious side effects including neutropenia, hypoesthesia, and thrombocytopenia. The study highlights the need for clinicians to address these toxicities in ADCs' use.
Researchers at Weill Cornell Medicine have identified an ultrapotent IgM antibody that neutralizes the Zika virus and prevents infection in preclinical models. The discovery could lead to the development of therapies to protect babies from birth defects caused by Zika.
A recent study from Linköping University found that COVID-19 reactivated several latent viruses, including the Epstein-Barr virus, in people with chronic fatigue syndrome (ME/CFS). The study suggests that these reactivated viruses may contribute to the disease's symptoms and could potentially be used as a diagnostic tool.
A research team developed a vaccine targeting synthetic opioid fentanyl to block its entry into the brain, preventing fatal effects. The breakthrough could have major implications for treating Opioid Use Disorder, with potential relapse prevention capabilities.
A study analyzing seroprevalence data found that global COVID-19 infection rates are likely higher than reported, with 59.2% of the population seropositive as of September 2021. The study suggests that two-thirds of the global population may have antibodies from vaccination or infection.
A study by Children's Hospital of Philadelphia researchers found that COVID-19 vaccination results in higher antibody concentrations compared to natural infection, providing robust protection for mothers during pregnancy. The study also suggests optimal vaccine timing can maximize the transfer of antibodies to babies.
Researchers found histamine releases HMGB1 in vascular endothelial cells, leading to severe symptoms. Administering anti-HMGB1 antibody attenuated hypotension and improved recovery rates.
A new study led by Duke-NUS Medical School scientists found that inactivated SARS-CoV-2 vaccines elicit a broad immune response against different proteins on the virus, while mRNA vaccines stimulate a single spike protein response. This broader T-cell response may be beneficial in preventing severe COVID-19 disease.
Scientists have elucidated the exact molecular structure of an IgM-type B cell receptor, revealing its asymmetrical complex with signaling subunits. The discovery provides insights into how the receptor interacts with other molecules and could lead to a better understanding of vaccine development and lymphoma formation.
Researchers found that elderly Japanese individuals show a low immune response to the third mRNA COVID-19 booster vaccine. The study revealed that nearly 10% of participants had negligible antibody production despite receiving an additional dose. The findings suggest that elderly people may require specialized serological testing proto...
Researchers discovered that B cells randomly allocate antibody classes to fight infections and diseases, leading to varying probabilities of developing conditions like asthma. This 'molecular roulette' process can be predicted using a formula, paving the way for understanding individual susceptibility.
A Johns Hopkins Medicine study found that COVID-19 booster shots are essential for maintaining long-term immunity against infection, particularly among older adults. The results support the CDC vaccination guidelines recommending COVID-19 boosters and highlight the importance of continued research on factors affecting immunity.
A recent study finds that exposure to proteins in common foods, vaccines, bacteria, and viruses can prime the immune system to attack SARS-CoV-2, potentially providing protection against COVID-19. The study's findings suggest that individuals with a history of exposure to these agents may be less susceptible to severe illness.
A newly discovered sarbecovirus in Russian bats has the ability to use human ACE2 to enter cells and is resistant to antibodies from people vaccinated against SARS-CoV-2. This finding highlights the potential risk of transmission between animals and humans.
A study by Karolinska Institutet found that children with primary immunodeficiency diseases have a higher mortality rate due to COVID-19. Genetic analysis revealed mutations in genes important for immune defense, and some children lacked antibodies to the coronavirus.
A recent study found that the immune response to COVID-19 booster vaccination decreases over five months, with a slower decline in antibody levels after the third dose compared to the second. The neutralizing response to the Omicron variant was also found to be lower than other variants of concern.
A study published in The New England Journal of Medicine found that mucosal antibodies in the airways significantly reduce the risk of omicron infection. High levels of these antibodies more than halved the risk of becoming infected, while also being associated with lower viral replication.
Researchers found that SARS-CoV-2 antibody levels remained high for at least 6 months after vaccination, providing long-term protection against subsequent infection. The study involved 2,100 West Virginia nursing home residents and staff who received COVID-19 vaccination.
A study by researchers at Linköping University suggests that severe COVID-19 infection has long-lasting negative effects on the immune system. The results showed that patients developed antibodies against SARS-CoV-2 within 2-3 weeks of symptoms, which then started to fall after six months.
Researchers have identified two effective antibodies that neutralize all known strains of COVID-19, including Delta and Omicron variants. These breakthrough antibodies could eliminate the need for repeated booster vaccinations and strengthen immune systems, especially in at-risk populations.
A Tel Aviv University study challenges the widely-held assumption that COVID-19 originated from bats, instead highlighting their highly effective immune system. The researchers found that many reported findings on bat-borne viruses are based on antibody presence or PCR tests rather than actual virus isolation.
Researchers discovered a substance that increased immune response to an experimental COVID-19 shot in mice, producing antibodies 25 times greater than without an adjuvant. The new adjuvant, αGC-CPOEt, is being investigated as a potential treatment for COVID-19 and other infectious diseases.
Researchers at Indian Institute of Science create a novel virus-like particle (VLP) to safely study SARS-CoV-2 mutations and trigger an immune response. The VLP is stable, can attach to host cells, and elicit antibodies that neutralize the live virus.
Researchers have found that human antibodies can incorporate foreign genetic material from the mitochondria and ends of chromosomes, leading to increased immune diversity. This discovery challenges the long-held assumption that antibody diversity results solely from gene mutations.
A new study from Cedars-Sinai researchers found that 56% of people infected with the Omicron variant were unaware they had COVID-19. The study suggests that a lack of infection awareness contributed to the fast spread of Omicron.
A 3-dose Moderna COVID-19 vaccination schedule significantly improved SARS-CoV-2 antibody concentrations in immunocompromised patients. This improvement was comparable to those obtained by healthy individuals after the standard two-dose Moderna vaccination schedule.
Researchers found that Merkel cell carcinoma (MCC) Glypican-3 (GPC3) is expressed in nearly 70% of MCC tumors and up to 90% of MCPyV-negative cases. GPC3 expression is associated with worse prognosis, including increased risk of death from MCC. This makes GPC3 a promising target for chimeric antigen receptor T cell therapy.
Boosting with either Janssen or Pfizer-BioNTech vaccine boosts humoral and cellular immune responses. Boosting with Janssen vaccine provides durable antibody and T-cell responses for at least four months.
Researchers have discovered a broadly neutralising antibody, ZCB11, that protects against all SARS-CoV-2 Omicron variants. Administration of ZCB11 either prophylactically or therapeutically shields lung infection in golden Syrian hamsters from Omicron viral challenge.
A new study by Tokyo University of Science researchers reveals that dendritic cell immunoreceptor (DCIR) plays a crucial role in the development of colorectal tumors. Blocking DCIR may prevent ulcerative colitis and colon cancer, offering a potential therapeutic target for treating these diseases.
The new phage T4-COVID-19 vaccine elicits superior mucosal immunity in mice, inducing robust humoral and cell-mediated immune responses. The vaccine provides complete protection against SARS-CoV-2 variants with minimal lung lesions and no impact on gut microbiota.
Researchers have created a nanobody that can penetrate tough brain cell coatings and disrupt alpha-synuclein clumps, which contribute to neurodegenerative diseases. The nanobody, PFFNB2, shows promise in preventing disease progression in live mouse brains.
CoVaRR-Net is investing $6.9 million in 15 research projects focused on understanding Omicron subvariants and finding solutions to curb their spread. The studies will explore various aspects of variants, including viral transmission between animals and people, new variant mutations, and the impact of social factors on Indigenous Peoples.
A study by Goethe University Frankfurt found that antibodies against Omicron variants BA.1 and BA.2 decline rapidly, even after a second vaccination or booster shot, offering limited protection against infection.
A new study found that adults have stable immune memory to common cold coronaviruses, which could lead to similar protection against SARS-CoV-2. The findings suggest that COVID-19 booster shots may be critical for long-term immunity.
Researchers from Indiana University are developing a new biosensor that can analyze samples from 96 individuals in under three hours, with a sensitivity rate of 100% and specificity rate of 90%. The sensor detects not only the virus's spike protein but also the proteins created by the body to protect against the virus.
A recent study found higher antibody titers after the third and fourth Pfizer-BioNTech vaccine doses in individuals aged 60 or older. This population is at high risk of severe SARS-CoV-2 disease, making timely vaccination crucial.